Literature DB >> 25523498

Possible adverse effects of SGLT2 inhibitors on bone.

Simeon I Taylor1, Jenny E Blau2, Kristina I Rother2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25523498      PMCID： PMC4900761          DOI： 10.1016/S2213-8587(14)70227-X

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN： 2213-8587            Impact factor:   32.069


× No keyword cloud information.
  10 in total

1.  Bone as a source of FGF23: regulation by phosphate?

Authors:  Michiko Mirams; Bruce G Robinson; Rebecca S Mason; Anne E Nelson
Journal:  Bone       Date:  2004-11       Impact factor: 4.398

Review 2.  Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism.

Authors:  L Darryl Quarles
Journal:  Nat Rev Endocrinol       Date:  2012-01-17       Impact factor: 43.330

3.  Effect of phloridzin on uric acid excretion in man.

Authors:  M D Skeith; L A Healey; R E Cutler
Journal:  Am J Physiol       Date:  1970-10

4.  The role of phosphate in the secretion of parathyroid hormone in man.

Authors:  E Reiss; J M Canterbury; M A Bercovitz; E L Kaplan
Journal:  J Clin Invest       Date:  1970-11       Impact factor: 14.808

5.  Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women.

Authors:  Sherri -Ann M Burnett; Samantha C Gunawardene; F Richard Bringhurst; Harald Jüppner; Hang Lee; Joel S Finkelstein
Journal:  J Bone Miner Res       Date:  2006-08       Impact factor: 6.741

6.  Nonclinical toxicology assessments support the chronic safety of dapagliflozin, a first-in-class sodium-glucose cotransporter 2 inhibitor.

Authors:  Mark Tirmenstein; Thomas E Dorr; Evan B Janovitz; Deborah Hagan; Lynn M Abell; Joelle M Onorato; Jean M Whaley; Michael J Graziano; Timothy P Reilly
Journal:  Int J Toxicol       Date:  2013-10-04       Impact factor: 2.032

7.  Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects.

Authors:  B Komoroski; N Vachharajani; D Boulton; D Kornhauser; M Geraldes; L Li; M Pfister
Journal:  Clin Pharmacol Ther       Date:  2009-01-07       Impact factor: 6.875

8.  Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).

Authors:  Steven E Kahn; Bernard Zinman; John M Lachin; Steven M Haffner; William H Herman; Rury R Holman; Barbara G Kravitz; Dahong Yu; Mark A Heise; R Paul Aftring; Giancarlo Viberti
Journal:  Diabetes Care       Date:  2008-01-25       Impact factor: 19.112

Review 9.  SGLT inhibitors in management of diabetes.

Authors:  Abd A Tahrani; Anthony H Barnett; Clifford J Bailey
Journal:  Lancet Diabetes Endocrinol       Date:  2013-08-13       Impact factor: 32.069

10.  Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control.

Authors:  Donald E Kohan; Paola Fioretto; Weihua Tang; James F List
Journal:  Kidney Int       Date:  2013-09-25       Impact factor: 10.612
  10 in total
  76 in total

Review 1.  Glucose-Lowering Therapies for Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: State-of-the-Art Review.

Authors:  Salvatore Carbone; Dave L Dixon; Leo F Buckley; Antonio Abbate
Journal:  Mayo Clin Proc       Date:  2018-11       Impact factor: 7.616

Review 2.  Diabetes pharmacotherapy and effects on the musculoskeletal system.

Authors:  Evangelia Kalaitzoglou; John L Fowlkes; Iuliana Popescu; Kathryn M Thrailkill
Journal:  Diabetes Metab Res Rev       Date:  2018-12-20       Impact factor: 4.876

Review 3.  SGLT2 inhibitors in the management of type 2 diabetes.

Authors:  R P Monica Reddy; Silvio E Inzucchi
Journal:  Endocrine       Date:  2016-06-07       Impact factor: 3.633

4.  A role for tubular Na+/H+ exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin.

Authors:  Akira Onishi; Yiling Fu; Rohit Patel; Manjula Darshi; Maria Crespo-Masip; Winnie Huang; Panai Song; Brent Freeman; Young Chul Kim; Manoocher Soleimani; Kumar Sharma; Scott Culver Thomson; Volker Vallon
Journal:  Am J Physiol Renal Physiol       Date:  2020-09-07

5.  The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes.

Authors:  Kathryn M Thrailkill; Jeffry S Nyman; R Clay Bunn; Sasidhar Uppuganti; Katherine L Thompson; Charles K Lumpkin; Evangelia Kalaitzoglou; John L Fowlkes
Journal:  Bone       Date:  2016-10-28       Impact factor: 4.398

Review 6.  Are SGLT2 inhibitors reasonable antihypertensive drugs and renoprotective?

Authors:  J A Lovshin; R E Gilbert
Journal:  Curr Hypertens Rep       Date:  2015-06       Impact factor: 5.369

Review 7.  Effects of Incretin-Based Therapies and SGLT2 Inhibitors on Skeletal Health.

Authors:  Andrea Egger; Marius E Kraenzlin; Christian Meier
Journal:  Curr Osteoporos Rep       Date:  2016-12       Impact factor: 5.096

8.  Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials.

Authors:  Huilin Tang; Xi Zhang; Jingjing Zhang; Yufeng Li; Liana C Del Gobbo; Suodi Zhai; Yiqing Song
Journal:  Diabetologia       Date:  2016-09-15       Impact factor: 10.122

Review 9.  Bone Fractures with Sodium-Glucose Co-transporter-2 Inhibitors: How Real is the Risk?

Authors:  Edoardo Mannucci; Matteo Monami
Journal:  Drug Saf       Date:  2017-02       Impact factor: 5.606

10.  SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice.

Authors:  Kathryn M Thrailkill; R Clay Bunn; Jeffry S Nyman; Mallikarjuna R Rettiganti; Gael E Cockrell; Elizabeth C Wahl; Sasidhar Uppuganti; Charles K Lumpkin; John L Fowlkes
Journal:  Bone       Date:  2015-07-23       Impact factor: 4.398
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.